NCT01206088View on ClinicalTrials.gov

Tasigna in Glivec-resistant or Intolerant Patients in CML

PHASE4CompletedINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions
CMLNilotinibImatinib ResistantImatinib Intolerant
Interventions
DRUG

nilotinib

administration of nilotinib as 2nd line

Trial Locations (1)

Unknown

St. Mary hospital, Catholic medical center, Seoul

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY